Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273070 | 0.77 | CDK5 (0.48) | — | |
| SCHEMBL3269031 | 0.72 | PDGFRB (0.32) | — | |
| SCHEMBL3275293 | 0.69 | CYP3A4 (0.40) | — | |
| SCHEMBL3269209 | 0.69 | HPGDS (0.38) | IDO1 | |
| 2,6-Diaminopurine SCHEMBL2316818 | 0.68 | KDM4E (0.32) | — | |
| SCHEMBL3273300 | 0.67 | CCR1 (0.42) | — | |
| 6-Chloroguanine SCHEMBL3268234 | 0.65 | MMP12 (0.33) | — | |
| SCHEMBL3269477 | 0.65 | L3MBTL1 (0.35) | — | |
| SCHEMBL3272888 | 0.65 | CDK5 (0.49) | — | |
| SCHEMBL3269217 | 0.64 | ADORA2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | IDO1 1809/4885CHEK1 2695/4885CHEK2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.